Work

Cancer Therapy–Induced Cardiotoxicity: Basic Mechanisms and Potential Cardioprotective Therapies

Year: 2014

Type: review

Abstract: PresentationT he patient is a 63-year-old man with a history of well- controlled hypertension who is diagnosed with diffuse large B-cell lymphoma and treated with a doxorubicincontaining chemotherapy regimen.During therapy, he is continued on hydrochlorothiazide for his hypertension.Three months later, he complains of dyspnea on exertion and mild lower extremity edema.A transthoracic echocardiogram reveals a moderately reduced left ventricular ejection fraction (LVEF), which is new compared with a study performed before he underwent chemotherapy.

Source: Journal of the American Heart Association

DOI: 10.1161/jaha.113.000665

Authors: Virginia Shalkey Hahn, Daniel J. Lenihan, Bonnie Ky

Institutions: University of Pennsylvania, Vanderbilt University

Language: English

Topic: Chemotherapy-induced cardiotoxicity and mitigation

Subfield: Cardiology and Cardiovascular Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: gold

Estimated APC paid: $3,810